The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
Eli Lilly and Company
Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes
with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of
obesity. In this study, the Anti-obesity Agent is being tested to see if it can treat weight
gain that may be associated with taking olanzapine.
The purposes of this study are to determine the safety of olanzapine when given in
combination with the Anti-obesity Agent and any side effects that might be associated with
it and whether weight-gain agent can help treat weight gain that may be associated with
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.